| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.61B | +13.1% |
| Gross profit | ¥0.18B | — |
| Operating income | ¥0.08B | — |
| Net income | ¥0.07B | -9.5% |
| Gross margin | 29.4% | Net margin 12.0% |
| Revenue Q/Q | +16.4% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.43B | 70.6% |
| R&D | ¥0.03B | 4.6% |
| SG&A | ¥0.07B | 10.8% |
| Tax & other | ¥0.01B | 1.3% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
工大科雅 ・ 喜悦智行 ・ 迈赫股份 ・ 大族数控 ・ 诚达药业 ・ 朗威股份 ・ 国泰环保 ・ 联特科技 ・ 三元生物 ・ 华兰疫苗 ・ 中亦科技 ・ 联合化学
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies